InnoScience (Suzhou) Technology Holding Co., Ltd.
英諾賽科(蘇州)科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2577)

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION; PROPOSED RE-ELECTION OF THE BOARD OF DIRECTORS; APPOINTMENT OF THE CHIEF EXECUTIVE OFFICER OF THE COMPANY; AND CHANGE OF CHIEF FINANCIAL OFFICER OF THE COMPANY

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

In view of the completion by InnoScience (Suzhou) Technology Holding Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") in June 2026 of the conversion of an aggregate of 373,841,270 domestic unlisted shares of the Company into H Shares of the Company, and in order to further improve the corporate governance structure and optimize the composition of the board of directors (the "**Board**") and senior management of the Company, the Board proposes to make corresponding amendments to the relevant provisions of the Articles of Association of InnoScience (Suzhou) Technology Holding Co., Ltd. (the "**Articles of Association**"). Details of the proposed amendments are set out in Appendix I to this announcement.

Save for the above amendments, the other provisions of the Articles of Association currently in effect will remain unchanged. The amended Articles of Association will take effect from the date on which they are considered and approved by way of special resolution at the extraordinary general meeting of the Company (the "**General Meeting**"). Prior to the amended Articles of Association becoming effective, the existing Articles of Association will remain in effect. The final amendments to the Articles of Association shall be subject to the version approved by the competent market regulatory authority.

Meanwhile, the Board proposes to request the General Meeting to authorize the Board and the person(s) authorized by the Board to handle, with full discretion, the specific matters relating to the amendments to the Articles of Association, including but not limited to making corresponding adjustments to the Articles of Association in accordance with the opinions or requirements of regulatory authorities and completing the relevant procedures for registration of the relevant changes with the market regulation authority.

PROPOSED RE-ELECTION OF THE BOARD OF DIRECTORS

Given that the term of office of the first session of the Board has expired, pursuant to the Company Law of the People's Republic of China (the "**Company Law**") and the Articles of Association, the Board has nominated the following non-employee representative Directors for the second session of the Board: (i) Dr. Weiwei Luo, Mr. Jay Hyung Son and Dr. Wu Jingang as candidates for executive Directors; (ii) Dr. Wang Can and Ms. Zhang Yanhong as candidates for non-executive Directors; and (iii) Mr. Wong Hin Wing, MH, JP, Dr. Yi Jiming and Dr. Yang, Simon Shi-Ning as candidates for independent non-executive Directors, for a term of three years commencing from the date of their election and approval by the General Meeting. Upon approval by the General Meeting, the above non-employee representative Director candidates, together with one employee representative Director elected at the employee representatives' meeting of the Company, will form the second session of the Board.

Following review at the second meeting of the Nomination Committee of the first session of the Board, the above Director candidates meet the qualification requirements for Directors under relevant laws, administrative regulations and normative documents, and none of them is subject to any circumstance under the Company Law, the Articles of Association or otherwise that would prohibit him/her from serving as a Director of the Company. The educational backgrounds and work experience of the three independent non-executive Director candidates enable them to discharge the duties of independent non-executive Directors. The biographies of the Director candidates are set out in Appendix II to this announcement.

Each of Mr. Wong Hin Wing, MH, JP, Dr. Yi Jiming and Dr. Yang, Simon Shi-Ning has confirmed that he satisfies the independence criteria set out in Rule 3.13(1) to (8) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Hong Kong Listing Rules**"), that he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person of the Company, and that there are no other factors that may affect his independence.

Save as disclosed in Appendix II to this announcement, each of the Director candidates has confirmed that: (i) he/she has not held any directorship in any other listed company in Hong Kong or overseas in the past three years, nor held any other position with the Company or any of its subsidiaries; (ii) he/she has no relationship with any Director, senior management, controlling shareholder or substantial shareholder of the Company; (iii) he/she does not have any interest in any shares of the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)); and (iv) there is no other information required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Hong Kong Listing Rules, nor is there any matter that needs to be brought to the attention of the shareholders of the Company (the "**Shareholders**").

Upon approval of their election by the General Meeting, the Director candidates will receive remuneration in accordance with the following standards: (i) the executive Directors will receive remuneration in accordance with the remuneration policies and systems of the Company based on the positions they hold in the Company, of which the estimated annual remuneration of Dr. Weiwei Luo is RMB4,612,441 (comprising salary of RMB3,255,625 and bonus of RMB1,356,816), the estimated annual remuneration of Dr. Wu Jingang is RMB6,999,996 (comprising salary of RMB3,999,996 and bonus of RMB3,000,000), and the estimated annual remuneration of Mr. Jay Hyung Son is RMB2,002,582 (being the amount of salary); (ii) the non-executive Directors will not receive remuneration from the Company; and (iii) the allowance for independent non-executive Directors is RMB40,000 per month (before tax). The above remuneration plan for Directors for 2026 was considered and approved at the 2025 annual general meeting of the Company held on May 22, 2026. The Company may adjust the remuneration plan with reference to industry conditions, actual operating conditions and the specific performance of the relevant personnel. For details of the actual remuneration, please refer to the disclosures in the annual report of the Company for each year.

Due to the re-election of the Board, Mr. Zhong Shan (a current executive Director and chief financial officer), Ms. Cui Mizi (a current non-executive Director) and Dr. Chan, Philip Ching Ho (a current independent non-executive Director) will cease to serve as Directors of the Company from the date on which the second session of the Board is elected by the General Meeting, and Dr. Chan, Philip Ching Ho will also cease to hold any position on the special committees of the Board of the Company. Mr. Zhong Shan, Ms. Cui Mizi and Dr. Chan, Philip Ching Ho have each confirmed that he/she has no disagreement with the Board and that there is no other matter relating to his/her retirement that needs to be brought to the attention of the Shareholders or The Stock Exchange of Hong Kong Limited (the "**Hong Kong Stock Exchange**").

To ensure the normal operation of the Board, prior to completion of the re-election of the Board, the first session of the Board will continue to perform its duties in accordance with the relevant laws and regulations and the Articles of Association.

APPOINTMENT OF THE CHIEF EXECUTIVE OFFICER OF THE COMPANY

Given that the term of office of the chief executive officer of the Company has expired, the Board has resolved to re-appoint Dr. Wu Jingang as the chief executive officer of the Company for a term of three years commencing from the date on which the Board resolution was passed (i.e. August 28, 2026).

Please refer to this announcement and Appendix II for Dr. Wu Jingang's remuneration, his confirmation in relation to the Hong Kong Listing Rules and details of his biography.

CHANGE OF CHIEF FINANCIAL OFFICER OF THE COMPANY

Given that the term of office of Mr. Zhong Shan as the chief financial officer of the Company has expired, the Board has resolved to appoint Ms. Wei Yu as the chief financial officer of the Company for a term of three years commencing from the date on which the Board resolution was passed (i.e. August 28, 2026). The biography of Ms. Wei Yu is set out in Appendix III to this announcement.

The retirement of Mr. Zhong Shan as the chief financial officer of the Company will take effect from August 28, 2026. He has confirmed that he has no disagreement with the Board in respect of his retirement as the chief financial officer and that there is no other matter relating to his retirement as the chief financial officer that needs to be brought to the attention of the Shareholders or the Hong Kong Stock Exchange. The Board would like to take this opportunity to express its gratitude to Mr. Zhong Shan for his valuable contributions to the Group during his tenure as the chief financial officer.

The Board would like to extend its warm welcome to Ms. Wei Yu on accepting her new appointment.

GENERAL

A circular containing, among other things, details of the proposed amendments to the Articles of Association and the proposed re-election of the Board of Directors will be published and/or despatched to the Shareholders who have requested printed copies in due course.

By order of the Board
InnoScience (Suzhou) Technology Holding Co., Ltd.
英諾賽科(蘇州)科技股份有限公司
Dr. Weiwei Luo
Chairperson and Executive Director

China, August 28, 2026

As at the date of this announcement, the Board of the Company comprises Dr. Weiwei Luo, Mr. Jay Hyung Son, Dr. Wu Jingang and Mr. Zhong Shan as executive directors; Dr. Wang Can, Ms. Zhang Yanhong and Ms. Cui Mizi as non-executive directors; and Mr. Wong Hin Wing, MH, JP, Dr. Yi Jiming, Dr. Yang, Simon Shi-Ning and Dr. Chan, Philip Ching Ho as independent non-executive directors.

Appendix I:

Comparison Table of Amendments to the Articles of Association

Article No.	Before Amendment	After Amendment
Article 3	The Company was established by way of promotion, registered with the Administration for Market Regulation of Suzhou Municipality (蘇州市市場監督管理局), has obtained business license, its unified social credit code is 91320509MA1PY5UE67. The number of issued shares of the Company is 915,100,653 shares, all of which are ordinary shares. These shares comprise 389,559,466 domestic unlisted shares, representing approximately 42.57% of the total number of shares of the Company, and 525,541,187 H shares, representing approximately 57.43% of the total number of shares of the Company.	The Company was established by way of promotion, registered with the Administration for Market Regulation of Suzhou Municipality (蘇州市市場監督管理局), has obtained business license, its unified social credit code is 91320509MA1PY5UE67. The number of issued shares of the Company is 915,100,653 shares, all of which are ordinary shares. These shares comprise **15,718,196** domestic unlisted shares, representing approximately **1.72%** of the total number of shares of the Company, and **899,382,457** H shares, representing approximately **98.28%** of the total number of shares of the Company.
Article 45	The general meeting of shareholders of the Company shall be composed of all shareholders. The general meeting of shareholders is the authority of power of the Company which shall exercise the following functions and powers in accordance with the laws: (I) elect and replace directors, decide on the remuneration matters of the relevant directors; (II) consider and approve the reports of the Board of Directors; (III) consider and approve the Company's profit distribution plans and loss recovery plans; (IV) pass resolutions to increase or reduce the registered capital of the Company; (V) pass resolutions on the issuance of corporate bonds;	The general meeting of shareholders of the Company shall be composed of all shareholders. The general meeting of shareholders is the authority of power of the Company which shall exercise the following functions and powers in accordance with the laws: (I) elect and replace directors, decide on the remuneration matters of the relevant directors; (II) consider and approve the reports of the Board of Directors; (III) consider and approve the Company's profit distribution plans and loss recovery plans; (IV) pass resolutions to increase or reduce the registered capital of the Company; (V) pass resolutions on the issuance of corporate bonds;

Article No.	Before Amendment	After Amendment
	(VI) pass resolutions on merger, division, dissolution and liquidation or change in corporate form of the Company; (VII) amend these Articles of Association; (VIII) decide on the matter of acquiring the shares of the Company under the circumstances stipulated in items (I) and (II) of Article 25 hereof; (IX) pass resolutions on the engagement or dismissal of accounting firms engaged in the audit work of the Company; (X) consider and approve the guarantee matters stipulated in Article 46 hereof; (XI) consider matters regarding the purchase and sale of material assets by the Company within one year for an amount exceeding 30% of the latest audited total assets of the Company; (XII) consider and approve the changes in the use of proceeds raised; (XIII) consider other matters which shall be decided by the general meetings of shareholders as stipulated by laws, administrative regulations, departmental rules, securities regulatory rules of the place where the Company's shares are listed or the Articles of Association. …	(VI) pass resolutions on merger, division, dissolution and liquidation or change in corporate form of the Company; (VII) amend these Articles of Association; (VIII) decide on the matter of acquiring the shares of the Company under the circumstances stipulated in items (I) and (II) of Article 25 hereof; (IX) pass resolutions on the engagement or dismissal of accounting firms engaged in the audit work of the Company; (X) consider and approve the guarantee matters stipulated in Article 46 hereof; (XI) consider matters regarding the purchase and sale of material assets by the Company within one year for an amount exceeding 30% of the latest audited total assets of the Company; (XII) consider and approve the changes in the use of proceeds raised; **<u>(XIII) consider equity incentive schemes and employee stock ownership plans;</u>** (XIV) consider other matters which shall be decided by the general meetings of shareholders as stipulated by laws, administrative regulations, departmental rules, securities regulatory rules of the place where the Company's shares are listed or the Articles of Association. …

Article No.	Before Amendment	After Amendment
Article 73	At the annual general meeting, the Board of Directors shall report their work in the previous year to the general meeting of shareholders.	At the annual general meeting, the Board of Directors shall report their work in the previous year to the general meeting of shareholders. **<u>Each independent non-executive Director shall also make a report on the performance of his/her duties</u>.**
Article 81	The following matters shall be approved by special resolutions at a general meeting: (I) increase or reduction in the registered capital of the Company; (II) division, split-up, merger, dissolution and voluntary liquidation of the Company; (III) amendment to the Articles of Association; (IV) the amounts for purchase or disposal of material asset or provision of guarantee to others by the Company within one year exceed 30% of the latest audited total assets of the Company; (V) other matters as required by laws, administrative regulations, securities regulatory rules of the place where the Company's shares are listed or the Articles of Association, and other matters considered to have material impact on the Company by ordinary resolution of the general meeting and approval by special resolution is required.	The following matters shall be approved by special resolutions at a general meeting: (I) increase or reduction in the registered capital of the Company; (II) division, split-up, merger, dissolution and voluntary liquidation of the Company; (III) amendment to the Articles of Association; (IV) the amounts for purchase or disposal of material asset or provision of guarantee to others by the Company within one year exceed 30% of the latest audited total assets of the Company; **<u>(V) equity incentive schemes;</u>** (VI) other matters as required by laws, administrative regulations, securities regulatory rules of the place where the Company's shares are listed or the Articles of Association, and other matters considered to have material impact on the Company by ordinary resolution of the general meeting and approval by special resolution is required.
Article 109	The Company shall have a Board of Directors. The Board of Directors consists of 11 directors. The Board of Directors consists of 1 chairman and 4 independent non-executive directors.	The Company shall have a Board of Directors. The Board of Directors consists of **<u>9</u>** directors, including **<u>3</u>** independent non-executive directors **<u>and 1 employee representative Director</u>**. The Board of Directors shall have 1 chairman**, <u>who shall be elected by more than half of all Directors</u>**.

Article No.	Before Amendment	After Amendment
Article 135	The Company has a general manager, who is appointed or dismissed by the Board of Directors. The Company has 1 financial controller, 1 secretary to the Board of Directors and 3 deputy general managers, who are appointed or dismissed by the Board of Directors upon recommendation by the general manager. The Company's general manager, financial controller, secretary to the Board of Directors, deputy general managers and other senior management recognized by the Company's Board of Directors are the Company's senior management. Directors may be employed concurrently as general managers, financial controllers or other senior management personnel.	The Company has a general manager, who is appointed or dismissed by the Board of Directors. The Company has 1 financial controller, 1 secretary to the Board of Directors and **<u>2</u>** deputy general managers, who are appointed or dismissed by the Board of Directors upon recommendation by the general manager. The Company's general manager, financial controller, secretary to the Board of Directors, deputy general managers and other senior management recognized by the Company's Board of Directors are the Company's senior management. Directors may be employed concurrently as general managers, financial controllers or other senior management personnel.

Appendix II:

Biographies of the Director Candidates

Executive Director Candidates:

Dr. Weiwei Luo ("Dr. Luo"), aged 57, is the founder, chairperson of the Board and an executive Director of the Company. She joined the Group and was appointed as a Director and the chairperson of the Board on July 17, 2017, and was appointed as an executive Director on May 21, 2024. She is responsible for the overall business development and strategic planning of the Group. Dr. Luo has also held various positions in several subsidiaries of the Group, including serving as the chairperson of the boards of directors of InnoScience (Suzhou) Semiconductor Technology Co., Ltd. and InnoScience (Shenzhen) Semiconductor Technology Co., Ltd. since October 2017 and November 2020, respectively.

Dr. Luo is a world-class scientist and visionary entrepreneur with extensive experience. Prior to founding the Company, Dr. Luo has been engaged in scientific research, project management and entrepreneurship for years. Dr. Luo is also currently a director of Stark Semiconductor Co., Ltd., which is primarily engaged in the research and development of display and micro-screen technology.

Dr. Luo received a doctorate degree in applied mathematics from Massey University in New Zealand.

Dr. Luo is interested or deemed to be interested in the Shares of the Company within the meaning of Part XV of the SFO as follows: (1) 49,209,305 Shares directly held by her; (2) as (i) the controller of InnoScience Holding Pte. Ltd. ("**Inno Holding**"), (ii) the ultimate general partner of Suzhou Innocore Enterprise Management Center L.P., (iii) the controller of Inno Investment (Hong Kong) Limited, (iv) the ultimate general partner of Shanghai Inno Youpeng Enterprise Consulting L.P., and (v) the general partner of Suzhou Wujiang District Xinsheng Dapeng Equity Investment Partnership (Limited Partnership), she is interested in an aggregate of 184,989,837 H Shares; and (3) 45,637,736 Shares held by Mr. Jay Hyung Son. Pursuant to the voting rights proxy agreement entered into between Dr. Luo and Mr. Son on November 24, 2024, Mr. Son confirmed that he has appointed and will appoint Dr. Luo as his true and lawful proxy to vote all Shares of the Company and Inno Holding in which Mr. Son has been and will be interested at any and all meetings of shareholders of the Company and Inno Holding (as the case may be), and on any and all actions taken by written consent of shareholders of the Company and Inno Holding (as the case may be).

Mr. Jay Hyung Son ("Mr. Son"), aged 65, is an executive Director of the Company. He joined the Group and was appointed as a Director on July 17, 2017, and was appointed as an executive Director on May 21, 2024. He is responsible for the business development of the Group. Prior to serving as a Director, Mr. Son served as the general manager of InnoScience (Suzhou) Semiconductor Technology Co., Ltd. from October 2017 to October 2023.

Mr. Son has leadership and entrepreneurship experience in the field of semiconductors. Mr. Son received a bachelor's degree of science from the Faculty of the College of Engineering of the University of California, Berkeley in the United States in August 1987.

Mr. Son is interested in 45,637,736 Shares and holds a short position in 17,000,000 Shares of the Company.

Dr. Wu Jingang ("Dr. Wu"), aged 60, is an executive Director and the chief executive officer of the Company. He joined the Group on November 5, 2022, was appointed as a Director on January 12, 2023, and was appointed as an executive Director on May 21, 2024. He is responsible for the overall business development and operation of the Group.

Dr. Wu has extensive experience in semiconductor technology development. Prior to joining the Group, Dr. Wu worked at Semiconductor Manufacturing International Corporation, a company listed on the Hong Kong Stock Exchange (stock code: 00981) and the Shanghai Stock Exchange (stock code: 688981), from 2001 to July 2021, with his last position as the R&D vice president. Dr. Wu served as the general manager of and was responsible for the management of Shandong Chanyan Microelectronics Technology Research Institute Co., Ltd. from July 2021 to November 2022.

Dr. Wu received a doctorate degree in physical chemistry from the Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences in the PRC in September 1994.

Dr. Wu is interested in 10,001,142 Shares of the Company.

Non-executive Director Candidates:

Dr. Wang Can ("Dr. Wang"), aged 43, is a non-executive Director of the Company. He joined the Group and was appointed as a Director on January 26, 2022, and was appointed as a non-executive Director on May 21, 2024. Dr. Wang has extensive experience in private equity investment and financial services.

Dr. Wang worked at China National Bluestar (Group) Co., Ltd. from July 2009 to April 2012 and served as the investment manager of Shenzhen Junfeng Entrepreneur Investment Fund Management Co., Ltd. from August 2012 to July 2013. Since August 2013, Dr. Wang has been working at CMB International Capital Management (Shenzhen) Co., Ltd. and is currently serving as an executive director.

Dr. Wang received a bachelor's degree in materials chemistry from Peking University in the PRC in June 2004 and a doctorate degree in physical chemistry from Peking University in the PRC in July 2009.

Ms. Zhang Yanhong ("Ms. Zhang"), aged 46, is a non-executive Director of the Company. She joined the Group and was appointed as a Director on January 26, 2022, and was appointed as a non-executive Director on May 21, 2024.

Ms. Zhang has extensive experience in private equity investment and financial services. Since September 2003, Ms. Zhang has successively served as a deputy manager, general manager and the chairperson of the board of Orient State-Owned Capital Investment Operation Co., Ltd. (formerly Wujiang Orient State-owned Assets Operation Co. Ltd.). Ms. Zhang also served as the general manager of Suzhou Ronghu Industry Investment Development Co., Ltd. from June 2019 to September 2020.

Ms. Zhang received a master's degree in administrative management from East China University of Science and Technology in the PRC in March 2010.

Independent Non-executive Director Candidates:

Mr. Wong Hin Wing ("Mr. Wong"), MH, JP, aged 64, is an independent non-executive Director of the Company. He joined the Group and was appointed as an independent non-executive Director of the Company on May 21, 2024.

Mr. Wong has extensive experience in corporate management and governance, investment management and advisory as well as accounting and finance. From July 1985 to September 1996, Mr. Wong worked successively as an auditor in an international audit firm for four years and the chief financial officer of a Hong Kong listed company for seven years. Subsequently in 1997, Mr. Wong co-founded Silk Road International Capital Limited (formerly known as Legend Capital Partners, Inc.), a licensed corporation under the SFO, and led the company as an executive director and the responsible officer for 23 years. Since 2020, Mr. Wong has been serving as a partner of Hermitage Capital HK Limited, a private equity firm licensed under the SFO.

At present, Mr. Wong serves as an independent non-executive director of the following companies: (i) Zhaoke Ophthalmology Limited, a company listed on the Hong Kong Stock Exchange (stock code: 06622), since April 2021; (ii) Kingmaker Footwear Holdings Limited, a company listed on the Hong Kong Stock Exchange (stock code: 01170), since January 2023; (iii) YNBY International Limited, a company listed on the Hong Kong Stock Exchange (stock code: 00030), since November 2023; and (iv) China Pacific Insurance (Group) Co., Ltd., a company listed on the Hong Kong Stock Exchange (stock code: 2601) and the Shanghai Stock Exchange (stock code: 601601), since January 2026.

Mr. Wong previously served as: (i) an independent non-executive director of Jiangxi Bank Co., Ltd., a company listed on the Hong Kong Stock Exchange (stock code: 01916), from February 2018 to August 2024; (ii) an independent non-executive director of C Cheng Holdings Limited, a company listed on the Hong Kong Stock Exchange (stock code: 01486), from April 2023 to July 2025; and (iii) a non-executive director of C Cheng Holdings Limited, a company listed on the Hong Kong Stock Exchange (stock code: 01486), from July 2025 to October 2025.

In addition to the above, Mr. Wong has been a member of the Anhui Provincial Committee of the Chinese People's Political Consultative Conference since January 2013. He has also been a member of the Medical Council of Hong Kong since January 2021, a member of the Advisory Committee on Enhancing Self-Reliance Through District Partnership (ESR) Programme since July 2022, and a member of the Council of the Hong Kong Metropolitan University since June 20, 2026. Mr. Wong has also been a member of the board of directors of Ocean Park Corporation since July 2022 and its Deputy Chairman since July 1, 2026.

Mr. Wong received a master's degree in Executive Business Administration (EMBA) from The Chinese University of Hong Kong in December 1996. He has been a fellow member of the Hong Kong Institute of Certified Public Accountants since July 1995, a fellow member of the Association of Chartered Certified Accountants since July 1992, a fellow member of the Institute of Chartered Accountants in England and Wales since March 2015, and a fellow member of The Hong Kong Institute of Directors since April 2002. Mr. Wong has also been a member of The Chartered Governance Institute since June 1995, a member of the American Institute of Certified Public Accountants since February 1991 and a chartered member of the Chartered Institute for Securities & Investment since March 2011. Mr. Wong was awarded the Medal of Honour by the Government of the Hong Kong Special Administrative Region in July 2021 and was appointed as a Justice of the Peace in July 2024.

Dr. Yi Jiming ("Dr. Yi"), aged 59, is an independent non-executive Director of the Company. He joined the Group and was appointed as an independent non-executive Director on May 21, 2024. Dr. Yi has extensive academic and legal experience. Dr. Yi was a professor at the faculty of law of Huazhong University of Science and Technology in the PRC. He was also a visiting scholar and an Edwards Fellow of Columbia Law School in the United States from 2005 to 2006. Dr. Yi has been a professor at the faculty of law of Peking University since August 2011. At present, Dr. Yi is serving and has served as an independent director of Huaneng Guicheng Trust Corp., Ltd. since May 2024 and Ping An Securities Company Limited since November 2022. Dr. Yi is currently serving as the Vice Chairman of the Fifth Council of China Trademark Association and Vice Chairman of the Eighth Council of the China Intellectual Property Research Society.

Dr. Yi received a master's degree in law and a doctorate degree in law from Peking University in 1999 and 2002, respectively.

Dr. Yang, Simon Shi-Ning ("Dr. Yang"), aged 67, is an independent non-executive Director of the Company. He joined the Group and was appointed as an independent non-executive Director on May 21, 2024. Dr. Yang has extensive experience in the semiconductor industry. Dr. Yang is currently the chairman of the board of Wuhan Xinxin Integrated Circuit Manufacturing Holding Co., Ltd. Prior to that, Dr. Yang served at a number of renowned semiconductor companies, including successively serving as the senior vice president of technology development and manufacturing and the chief operating officer at Semiconductor Manufacturing International Corporation (a company listed on both the Hong Kong Stock Exchange (stock code: 00981) and the Shanghai Stock Exchange (stock code: 688981)), and the chief technology officer and senior vice president of Chartered Semiconductor Manufacturing, Inc.

Dr. Yang received a bachelor's degree from Shanghai University of Science and Technology in the PRC and a doctoral degree from Rensselaer Polytechnic Institute in the United States.

Appendix III:

Biography of the Chief Financial Officer

Ms. Wei Yu ("Ms. Wei"), aged 48, joined the Group in May 2026. Ms. Wei has over 22 years of experience in capital markets, investment and consulting. From April 2004 to July 2005, she served as a consultant at Capgemini SE, a multinational information technology services and consulting company, where she was primarily engaged in management consulting. From August 2005 to April 2008, she served as a strategy director at Schneider Logistics China, a logistics company, where she was primarily responsible for strategy. From April 2008 to April 2018, she served as a senior director of investor relations and strategic investment at Trip.com Group Limited (formerly known as Ctrip.com International, Ltd.), an online one-stop travel platform listed on the Hong Kong Stock Exchange (stock code: 9961) and the Nasdaq Stock Market (stock code: TCOM), where she was primarily responsible for investor relations and strategic investment. From April 2018 to June 2024, she served as vice president of capital markets at NIO Inc., an electric vehicle company listed on the Hong Kong Stock Exchange (stock code: 9866), the New York Stock Exchange (stock code: NIO) and the Singapore Exchange (stock code: NIO.SI). From July 2024 to June 2025, Ms. Wei served as the chief financial officer of Shanghai AutoFlight Co., Ltd., an electric vertical take-off and landing aircraft company in the PRC. On July 8, 2026, she was appointed as an independent non-executive director of MOMENTA GLOBAL LIMITED, a company listed on the Main Board of the Hong Kong Stock Exchange (stock code: 06880.HK).

Ms. Wei received a bachelor's degree in economics from the Central University of Finance and Economics in Beijing in July 1998 and a master's degree of arts in economics from the University of Arkansas in the United States in December 2001.